natgillin/translations-raw huggingface dataset:
Although more data are needed to determine the size of the benefit, the Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zalmoxis' benefits are greater than its risks and recommended that it be approved for use in the EU. 
Čeprav je za določitev obsega koristi potrebnih več podatkov, je Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji zaključil, da so koristi zdravila Zalmoxis večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Zalmoxis? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zalmoxis?
The number of patients who survived after one year was 51% for patients who received Zalmoxis compared with 34 to 40% for patients who did not receive Zalmoxis. 
Delež bolnikov, ki so preživeli eno leto, je bil 51 % pri bolnikih, ki so prejeli zdravilo Zalmoxis, v primerjavi s 34 do 40 % pri bolnikih, ki niso prejeli zdravila Zalmoxis.
It must also not be used in patients who have already developed graft-versus-host disease that requires treatment. 
Prav tako se ne sme uporabljati pri bolnikih, pri katerih se je že pojavila reakcija presadka proti gostitelju, zaradi katere je potrebno zdravljenje.
The safety profile of Zalmoxis is considered acceptable. 
Varnostni profil zdravila Zalmoxis je ocenjen kot sprejemljiv.
In this study, Zalmoxis was not compared with any other treatment. 
V tej študiji zdravila Zalmoxis niso primerjali z nobenim drugim zdravilom.
Zalmoxis is given as an infusion (drip) into a vein lasting 20 to 60 minutes, every month for up to four months until the circulating T cells reach a certain level. 
Zdravilo Zalmoxis se daje z infundiranjem (kapalno infuzijo) v veno, ki traja od 20 do 60 minut, vsak mesec do največ štiri mesece, dokler celice T v obtoku ne dosežejo določene ravni.
The main measure of effectiveness was restoration of the immune system as measured by blood levels of T cells. 
Glavno merilo učinkovitosti je bila obnova imunskega sistema, izmerjena s količino celic T v krvi.
These T cells are then genetically modified to include a ‘suicide gene'. 
Te celice T se nato gensko spremenijo tako, da vključujejo „samomorilski gen“.
The summary of the opinion of the Committee for Orphan Medicinal Products for Zalmoxis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Zalmoxis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The company will also collect data from all patients treated with Zalmoxis through a registry and will monitor their progress after treatment to study long-term safety and effectiveness of the medicine. 
Družba bo poleg tega v registru zbrala podatke o vseh bolnikih, zdravljenih z zdravilom Zalmoxis, in spremljala njihov napredek po zdravljenju, da bi preučila dolgoročno varnost in učinkovitost zdravila.
77% of the patients receiving Zalmoxis (23 out of 30) had their immune systems restored. 
Pri 77 % bolnikov (23 od 30), ki so prejeli zdravilo Zalmoxis , se je imunski sistem obnovil.
Data from the main study were also combined with data from a second ongoing study, and survival rates for 37 patients treated with Zalmoxis (23 from the main study and 14 from the ongoing study) were compared with rates from a patient database of 140 patients who have undergone haploidentical HSCT in the past. 
Podatke iz glavne študije so združili tudi s podatki iz druge študije, ki še poteka, in primerjali stopnje preživetja za 37 bolnikov, zdravljenih z zdravilom Zalmoxis (23 iz glavne študije in 14 iz študije, ki še poteka), in stopnje preživetja iz podatkovne zbirke s 140 bolniki, ki so v preteklosti prejeli haploidentični HSCT.
Graftversus-host disease occurred in 10 patients who were then given ganciclovir or valganciclovir, either alone or in combination with other medicines. 
Reakcija presadka proti gostitelju se je pojavila pri 10 bolnikih, ki so nato prejeli ganciklovir ali valganciklovir, samega ali v kombinaciji z drugimi zdravili.
The most common side effect with Zalmoxis (which may affect more than 1 in 10 people) is acute graft-versus-host disease (where the condition develops within approximately 100 days of the transplant). 
Najpogostejši neželeni učinek zdravila Zalmoxis (ki se lahko pojavi pri več kot 1 bolniku od 10) je akutna reakcija presadka proti gostitelju (ta se pojavi v približno 100 dneh po presaditvi).
Other information about Zalmoxis 
Druge informacije o zdravilu Zalmoxis
The company that markets Zalmoxis will provide educational material for healthcare professionals with detailed information on the risks, including graft-versus-host disease, and how to use the medicine correctly. 
Družba, ki trži zdravilo Zalmoxis, bo zagotovila izobraževalno gradivo za zdravstvene delavce s podrobnimi informacijami o tveganjih, vključno z reakcijo presadka proti gostitelju, in o pravilni uporabi zdravila.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zalmoxis have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zalmoxis upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Zalmoxis must not be used in patients whose immune system has been restored. 
Zdravilo Zalmoxis se ne sme uporabljati pri bolnikih, pri katerih se je imunski sistem že obnovil.
Because the number of patients undergoing haploidentical HSCT is low, Zalmoxis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 20 October 2003. 
Ker je bolnikov, ki prejmejo haploidentični HSCT, malo, je bilo zdravilo Zalmoxis 20. oktobra 2003 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
The full EPAR for Zalmoxis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zalmoxis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Zalmoxis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Zalmoxis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Zalmoxis contains T cells (a type of white blood cell) that have been genetically modified1. 
Zdravilo Zalmoxis vsebuje celice T (vrsto belih krvnih celic), ki so bile gensko spremenjene1.
What is Zalmoxis and what is it used for? 
Kaj je zdravilo Zalmoxis in za kaj se uporablja?
For the full list of restrictions and side effects reported with Zalmoxis, see the package leaflet. 
Za celoten seznam omejitev in neželenih učinkov, o katerih so poročali pri uporabi zdravila Zalmoxis, glejte navodilo za uporabo.
When given after transplantation, Zalmoxis helps the patient to build up their immune system and so helps to protect them from infections. 
Kadar se daje po presaditvi, zdravilo Zalmoxis bolniku pomaga obnoviti imunski sistem in mu tako pomaga pri zaščiti pred okužbami.
However the T cells in Zalmoxis can sometimes attack the patient's body, causing graft-versus-host disease. 
Vendar pa lahko celice T v zdravilu Zalmoxis včasih napadejo bolnikovo telo in povzročijo reakcijo presadka proti gostitelju.
Before receiving an HSCT, the patient will have received treatment to remove existing cells from the bone marrow, including cancer cells and immune cells. 
Pred prejemom HSCT bolnik prejme zdravilo, s katerim se odstranijo obstoječe celice iz kostnega mozga, vključno z rakavimi in imunskimi celicami.
What benefits of Zalmoxis have been shown in studies? 
Kakšne koristi je zdravilo Zalmoxis izkazalo v študijah?
What are the risks associated with Zalmoxis? 
Kakšna tveganja so povezana z zdravilom Zalmoxis?
Zalmoxis is a medicine used as an add-on treatment in adults who have received a haematopoietic stem cell transplant (HSCT, a transplant of cells that can develop into different types of blood cells) from a partially matched donor (a so-called haploidentical transplant). 
Zalmoxis je zdravilo, ki se uporablja kot dodatno zdravljenje pri odraslih, ki so prejeli presadek hematopoetskih matičnih celic (HSCT, presadek celic, ki se lahko razvijejo v različne vrste krvnih celic) od delno skladnega darovalca (t. i. haploidentični presadek).
For practical information about using Zalmoxis, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Zalmoxis naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Since Zalmoxis has been granted a conditional approval, the company that markets Zalmoxis will provide the results of an ongoing study in high-risk acute leukaemia patients. 
Ker je zdravilo Zalmoxis pridobilo pogojno dovoljenje za promet, bo družba, ki ga trži, zagotovila rezultate študije, ki še poteka pri bolnikih z akutno levkemijo z velikim tveganjem.
The T cells in Zalmoxis have a suicide gene, which makes them susceptible to the medicines ganciclovir and valganciclovir. 
Celice T v zdravilu Zalmoxis imajo samomorilski gen, zato so občutljive za zdravili ganciklovir in valganciklovir.
Zalmoxis is prepared for use in a specific patient. 
Zdravilo Zalmoxis se pripravi za uporabo pri posameznem bolniku.
The main risk is graft-versus-host disease, however this can be successfully treated with ganciclovir or valganciclovir, which kill the T cells in Zalmoxis. 
Glavno tveganje je reakcija presadka proti gostitelju, vendar se lahko ta uspešno zdravi z ganciklovirjem ali valganciklovirjem, ki uničita celice T v zdravilu Zalmoxis.
Why is Zalmoxis approved? 
Zakaj je bilo zdravilo Zalmoxis odobreno?
To make Zalmoxis, T cells from the HSCT donor are separated from the rest of the cells in the transplant. 
Pri izdelavi zdravila Zalmoxis se celice T darovalca HSCT ločijo od drugih celic v presadku.
The study will compare haploidentical HSCT followed by treatment with Zalmoxis with haploidentical HSCT containing T cells followed by treatment with cyclophosphamide (a medicine to prevent graft-versus-host disease) and with haploidentical HSCT without T cells. 
V študiji bodo primerjali haploidentični HSCT, ki mu sledi zdravljenje z zdravilom Zalmoxis, haploidentični HSCT s celicami T, ki mu sledi zdravljenje s ciklofosfamidom (zdravilom za preprečevanje reakcije presadka proti gostitelju), in haploidentični HSCT brez celic T.
It is not intended to provide practical advice on how to use Zalmoxis. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Zalmoxis has been investigated in a main study involving 30 patients who had haploidentical HSCT for serious blood cancers. 
Zdravilo Zalmoxis so preiskovali v glavni študiji, ki je vključevala 30 bolnikov, ki so prejeli haploidentični HSCT zaradi hudega krvnega raka.
What information is still awaited for Zalmoxis? 
Katere informacije o zdravilu Zalmoxis še pričakujemo?
Zalmoxis has been given ‘conditional approval'. 
Zdravilo Zalmoxis je pridobilo „pogojno dovoljenje za promet“.
All 10 patients recovered from graft-versus-host disease. 
Pri vseh 10 bolnikih je bilo zdravljenje reakcije presadka proti gostitelju uspešno.
Zalmoxis is a type of advanced therapy medicine called a ‘somatic cell therapy product'. 
Zdravilo Zalmoxis spada v skupino zdravil za napredno zdravljenje, ki se imenujejo „zdravila za somatsko celično zdravljenje“.
Zalmoxis is used in patients who have received a haploidentical HSCT because they have serious blood cancers, such as certain leukaemias and lymphomas. 
Zdravilo Zalmoxis se uporablja pri bolnikih, ki so prejeli haploidentični HSCT zaradi hudega krvnega raka, kot so nekatere levkemije in limfomi.
Zalmoxis can only be obtained with a prescription and treatment is given under the supervision of a doctor who has experience in the treatment of blood cancers using HSCT. 
Predpisovanje in izdaja zdravila Zalmoxis je le na recept, zdravljenje z njim pa mora biti pod nadzorom zdravnika z izkušnjami pri zdravljenju krvnega raka s HSCT.
The dose of Zalmoxis depends on the bodyweight of the patient. 
Odmerek zdravila Zalmoxis je odvisen od telesne mase bolnika.
If the patient develops graftversus-host disease, ganciclovir or valganciclovir is given, which kills the T cells that have the suicide gene thereby treating the disease and preventing its further development. 
Bolniki, pri katerih se pojavi reakcija presadka proti gostitelju, prejmejo ganciklovir ali valganciklovir, ki uniči celice T s samomorilskim genom in tako ozdravi reakcijo ter prepreči njen nadaljnji razvoj.
Zalmoxis is given to help restore the patient's immune system after the transplant. 
Dajanje zdravila Zalmoxis pripomore k obnovi bolnikovega imunskega sistema po presaditvi.
When using Zalmoxis, this can be treated with ganciclovir or valganciclovir. 
Pri uporabi zdravila Zalmoxis se reakcija lahko zdravi z ganciklovirjem ali valganciklovirjem.
How does Zalmoxis work? 
Kako zdravilo Zalmoxis deluje?
How is Zalmoxis used? 
Kako se zdravilo Zalmoxis uporablja?
Zalmoxis has been shown to help restore the immune systems of patients who had haploidentical HSCT for serious blood cancers; these patients have limited treatment options and a poor prognosis. 
Dokazali so, da zdravilo Zalmoxis pripomore k obnovi imunskega sistema bolnikov, ki so prejeli haploidentični HSCT zaradi hudega krvnega raka.
Most people will not have come into contact with it and therefore will not have built up protection (‘immunity') against it. 
Večina ljudi z njim ne bo prišla v stik in zato proti njemu ne bo razvila zaščite („imunosti“).
A flu pandemic can affect people worldwide and cause many deaths. 
Pandemija gripe lahko prizadene ljudi po vsem svetu in povzroči veliko smrtnih žrtev.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that preparing for a potential flu pandemic in children and adolescents meets an important medical need. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je ugotovil, da priprava na morebitno pandemijo gripe pri otrocih in mladostnikih izpolnjuje pomembno zdravstveno potrebo.
This helps to protect against the flu that the virus causes. 
To prispeva k obrambi pred gripo, ki jo ta virus povzroča.
It should be given in an officially declared pandemic and according to official guidance. 
Cepivo se sme dati v primeru uradno razglašene pandemije in v skladu z uradnimi smernicami.
This vaccine is intended to help with the management of a future pandemic. 
Namenjeno je za pomoč pri obvladovanju prihodnje pandemije.
It can particularly affect children who have not had seasonal flu or received flu vaccines previously. 
Prizadene lahko zlasti otroke, ki niso preboleli sezonske gripe in niso bili predhodno cepljeni proti gripi.
However, in a pandemic, it might be appropriate to give it to children with allergies if facilities for medical treatment of severe allergic reactions are immediately available. 
Vendar bi ga bilo v primeru pandemije morda smiselno dati tudi otrokom z alergijami, če je nemudoma na voljo ustrezno zdravljenje za primer alergijske reakcije.
Two doses of the vaccine are recommended and the child should receive the second dose at least 4 weeks after the first. 
Otrok mora drugi odmerek cepiva prejeti vsaj štiri tedne po prejemu prvega odmerka.
A flu pandemic occurs when a new strain of flu virus appears that can spread easily because people have no immunity (protection) against it. 
Pandemija nastopi, ko se pojavi nov sev virusa gripe, ki se lahko brez težav širi s človeka na človeka, ker ljudje proti njej niso imuni (zaščiteni pred njim).
In addition, there is evidence indicating that the vaccine can protect against different strains of H5N1 virus. 
Obstajajo tudi dokazi, da lahko cepivo daje zaščito pred različnimi sevi virusa H5N1.
When a child is given the vaccine, the immune system recognises the weakened virus in the vaccine as foreign and makes antibodies against it. 
Ko otrok prejme cepivo, imunski sistem prepozna oslabljeni virus kot tujek in proti njemu tvori protitelesa.
Testing this pandemic preparedness vaccine helps to predict how people will react to the vaccine at the time of a pandemic, when the virus strain in the vaccine will be replaced by a weakened version of the actual strain causing the pandemic. 
Preizkušanje takega cepiva za pripravljenost na pandemijo pomaga predvideti, kako se bodo ljudje nanj odzvali v času pandemije, ko bo sev virusa v cepivu nadomeščen z oslabljeno različico seva, ki bo dejansko povzročil pandemijo.
The results were similar to those from three other studies involving 170 adults given pandemic preparedness vaccines containing similar types of bird flu virus, such as H7N9 and H7N7, instead of H5N1. 
Rezultati so bili podobni rezultatom treh drugih študij, v katerih je 170 odraslih prejelo cepiva za pripravljenost na pandemijo, ki so namesto virusa H5N1 vsebovala podobne vrste virusov ptičje gripe, kot sta H7N9 in H7N7.
It is not possible to prepare a vaccine for a future pandemic because the strain of the pandemic flu virus is not known in advance. 
Cepiva za prihodnjo pandemijo ni mogoče pripraviti, saj sev virusa pandemske gripe ni vnaprej znan.
Pandemic influenza vaccine H5N1 AstraZeneca must not generally be given to children who have had a severe allergic reaction to any of the substances in the vaccine including gelatin and gentamicin or to children who have had a severe allergic reaction to eggs or egg proteins, such as ovalbumin. 
Cepivo proti pandemski gripi H5N1 AstraZeneca se v splošnem ne sme dati otrokom, ki so imeli hudo alergijsko reakcijo na katero koli snov v cepivu, vključno z želatino in gentamicinom, ter otrokom, ki so imeli hudo alergijsko reakcijo na jajca ali jajčne beljakovine, npr. ovalbumin.
Instead, a pandemic preparedness vaccine can be made to contain a bird flu virus strain that could potentially cause a future pandemic. 
Namesto tega se lahko izdela cepivo za pripravljenost na pandemijo, ki vsebuje sev virusa ptičje gripe, ki bi morda lahko povzročil prihodnjo pandemijo.
A vaccine against a specific disease ‘teaches' the immune system (the body's natural defences) to defend itself against the disease. 
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo‟, kako naj se brani pred boleznijo.
Because a new pandemic live attenuated vaccine cannot be tested in children, the benefit of this vaccine in children was predicted from studies in adults and from studies of similar live attenuated flu vaccines in children. 
Ker novega pandemskega živega oslabljenega cepiva ni mogoče preizkusiti na otrocih, so bile koristi tega cepiva pri njih predvidene na podlagi študij pri odraslih in študij podobnih živih oslabljenih cepiv proti gripi pri otrocih.
In those who received the second vaccine 3 weeks to 5 years after vaccination with Pandemic influenza vaccine H5N1 AstraZeneca, antibodies increased 4-fold in 73% (8 out of 11) of the individuals compared with 10% of the individuals who had not been previously vaccinated with Pandemic influenza vaccine H5N1 AstraZeneca. 
Pri tistih, ki so drugo cepivo prejeli v obdobju od treh tednov do petih let po cepljenju s cepivom proti pandemski gripi H5N1 AstraZeneca, so protitelesa štirikratno porasla pri 73 % (8 od 11) oseb, v primerjavi z 10 % oseb, ki predhodno niso bile cepljene s cepivom proti pandemski gripi H5N1
The full EPAR for Pandemic influenza vaccine H5N1 AstraZeneca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za cepivo proti pandemski gripi H5N1 AstraZeneca je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Pandemic influenza vaccine H5N1 MedImmune on 20 May 2016. 
Evropska komisija je dovoljenje za promet s cepivom proti pandemski gripi H5N1 MedImmune, veljavno po vsej Evropski uniji, izdala 20. maja 2016.
The most common side effects with Pandemic influenza vaccine H5N1 AstraZeneca (which may affect more than 1 in 10 people) are decreased appetite, headache, runny or stuffy nose, and feeling unwell. 
Najpogostejši neželeni učinki cepiva proti pandemski gripi H5N1 AstraZeneca (ki lahko prizadenejo več kot 1 osebo od 10) so zmanjšan tek, glavobol, izcedek iz nosu, zamašen nos in slabo počutje.
In addition, the company presented extensive supportive data from large studies and from clinical practice on how well other similar pandemic and seasonal live attenuated influenza A vaccines work in children. 
Poleg tega je družba predložila obsežne podporne podatke iz obsežnih študij in klinične prakse o učinkovitosti drugih podobnih pandemskih in sezonskih živih oslabljenih cepiv proti gripi A pri otrocih.
Pandemic influenza vaccine H5N1 AstraZeneca contains live, attenuated (weakened) influenza A virus A/Vietnam/1203/2004 (H5N1) strain. 
Cepivo proti pandemski gripi H5N1 AstraZeneca vsebuje živ, oslabljen sev virusa gripe A, in sicer sev A/Vietnam/1203/2004 (H5N1).
Pandemic influenza vaccine H5N1 AstraZeneca is a vaccine developed to protect children aged between 12 months and 18 years against influenza (flu) during a flu pandemic. 
Cepivo proti pandemski gripi H5N1 AstraZeneca je cepivo, ki so ga razvili za zaščito otrok, starih od 12 mesecev do 18 let, pred gripo med njeno pandemijo.
This is a summary of the European public assessment report (EPAR) for Pandemic influenza vaccine H5N1 AstraZeneca. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za cepivo proti pandemski gripi H5N1 AstraZeneca.
Thus, the CHMP decided that the benefits of the medicine in children aged 1 to 18 years are greater than its risks and recommended that it be given marketing authorisation. 
Odbor CHMP je zato zaključil, da so koristi cepiva proti pandemski gripi H5N1 AstraZeneca pri otrocih, starih od 1 do 18 let, večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
For more information about prevention of influenza with Pandemic influenza vaccine H5N1 AstraZeneca, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o preprečevanju gripe s cepivom proti pandemski gripi H5N1 AstraZeneca preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Three main studies involving 107 adults found that Pandemic influenza vaccine H5N1 AstraZeneca was able to prepare the immune system to defend itself against the H5N1 virus strain in individuals who had never come into contact with it. Antibodies against this type of vaccine are not easy to measure. 
Tri glavne študije, v katere je bilo vključenih 107 odraslih, so pokazale, da lahko cepivo proti pandemski gripi H5N1 AstraZeneca pripravi imunski sistem oseb, ki niso bile nikoli izpostavljene sevu virusa H5N1, da se brani pred njim.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pandemic influenza vaccine H5N1 AstraZeneca have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo cepiva proti pandemski gripi H5N1 AstraZeneca upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For practical information about using Pandemic influenza vaccine H5N1 AstraZeneca, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi cepiva proti pandemski gripi H5N1 AstraZeneca naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.